Skip to Content
Merck
All Photos(1)

Documents

A0362

Sigma-Aldrich

Adjuplex™ Vaccine Adjuvant

Concentrate, sterile

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
12352200
NACRES:
NA.25

sterility

sterile

quality

NOT FOR HUMAN USE

shipped in

wet ice

storage temp.

2-8°C

General description

Adjuplex potentiates immune responses to vaccines without reactogenicity and has demonstrated superiority to alum, Freund′s adjuvant, Ribi-R730 and numerous other experimental adjuvants. In laboratory animals, Adjuplex has been shown to improve the protective immune response to a variety of experimental human vaccines including HIV, influenza, rotavirus and malaria.

Application

Adjuplex is suitable for use with all types of antigens such as whole organism (live or inactivated), protein, polysaccharide, DNA, virus vector, and VLP. It is suitable for all routes of administration including intramuscular, subcutaneous, intradermal, and mucosal including intranasal.
Adjuplex™ Vaccine Adjuvant has been used to study the effects of adjuvants for DNA vaccination.

Other Notes

Adjuplex Vaccine Adjuvant is a non-denaturing adjuvant that does not contain oils, detergents, preservatives, or components of animal or bacterial origin. Adjuplex is is non-immunogenic and free of allergens, enzymes, mercury, aluminum, and other metals.

Quantity

One ml of Adjuplex is sufficient to formulate ten 0.5 ml doses of vaccine.

Legal Information

Adjuplex is a trademark of Advanced BioAdjuvants, LLC

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H319

Hazard Classifications

Eye Irrit. 2

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

  1. Which document(s) contains shelf-life or expiration date information for a given product?

    If available for a given product, the recommended re-test date or the expiration date can be found on the Certificate of Analysis.

  2. How do I get lot-specific information or a Certificate of Analysis?

    The lot specific COA document can be found by entering the lot number above under the "Documents" section.

  3. How do I find price and availability?

    There are several ways to find pricing and availability for our products. Once you log onto our website, you will find the price and availability displayed on the product detail page. You can contact any of our Customer Sales and Service offices to receive a quote.  USA customers:  1-800-325-3010 or view local office numbers.

  4. What is the Department of Transportation shipping information for this product?

    Transportation information can be found in Section 14 of the product's (M)SDS.To access the shipping information for this material, use the link on the product detail page for the product. 

  5. What is used to solubilize Adjuplex ™ Vaccine Adjuvant reagent, Product A0362? 

    The Adjuplex™ Vaccine Adjuvant reagent (Product No. A0362) can be solubilized in a sterile diluent such as phosphate buffered saline (PBS).  Endotoxin-free Dulbecco’s PBS without Ca2+ and Mg2+ is recommended, while unbuffered normal saline is NOT recommended.

  6. What are the adjuvant components of the Adjuplex™ Vaccine Adjuvant reagent, Product A0362? 

    The formulation of Adjuplex™ Vaccine Adjuvant reagent (Product A0362) is proprietary.  The formulation does not contain any components of animal-origin, microbial origin, or from recombinant technology.

  7. What is the recommended volume dose used with Adjuplex™ Vaccine Adjuvant reagent, Product A0362? 

    In general, the dosage volume of Adjuplex™ Vaccine Adjuvant (Product A0362) combined with antigen should be comparable to the dosage volumes used for other adjuvants.  Typical volumes are 0.1-0.2 mL for mice, 0.5 mL for rats and guinea pigs, and 1 mL for rabbits and goats, but these volumes are guidelines only.   For best effect, a dose response curve should be prepared.  

  8. What methods of administration are recommended for antigen preparations using Adjuplex™ Vaccine Adjuvant reagent, Product A0362? 

    Adjuplex™ Vaccine Adjuvant (Product A0362) has been found to be suitable for all routes of administration, including intramuscular, subcutaneous, intradermal, and mucosal including intranasal.  

  9. What types of antigen may be used with Adjuplex™ Vaccine Adjuvant reagent, Product A0362? 

    Adjuplex™ Vaccine Adjuvant (Product A0362) is suitable for use with all types of antigens including whole organism (live or inactivated), protein, polysaccharide, DNA, virus vector, and VLP antigens.  

  10. Can prepared solutions of antigen and Adjuplex™ Vaccine Adjuvant reagent, Product A0362, be stored and reused?

    We do not recommend reusing diluted solutions of Adjuplex™ Vaccine Adjuvant reagent (Product A0362) due to risk of contamination.  We recommend preparing fresh dilutions of Adjuplex™ Vaccine Adjuvant reagent with antigen each time prior to use.

  11. My question is not addressed here, how can I contact Technical Service for assistance?

    Ask a Scientist here.

Production of EV71 vaccine candidates.
Chong P, Hsieh SY, Liu CC, et al.
Human Vaccines & Immunotherapeutics, 8 (2012)
Jane E Libbey et al.
Vaccine, 29(17), 3356-3362 (2010-09-21)
Experimental autoimmune encephalomyelitis (EAE) is an experimental model for multiple sclerosis. EAE can be induced by inoculation with central nervous system (CNS) proteins or peptides emulsified in complete Freund's adjuvant. Protection from EAE, enhancement of EAE or subclinical priming for
Cornelis J M Melief
Journal of immunotherapy (Hagerstown, Md. : 1997), 35(3), 215-216 (2012-03-17)
Here, we review a novel vaccine modality, characterized by the administration of long (23 to 45 amino acids) synthetic peptides in incomplete Freund's adjuvant (mineral oil based, Montanide ISA-51), delivered subcutaneously. Such vaccines were first demonstrated to be much more
Rui Kong et al.
Cell, 178(3), 567-584 (2019-07-28)
The vaccine-mediated elicitation of antibodies (Abs) capable of neutralizing diverse HIV-1 strains has been a long-standing goal. To understand how broadly neutralizing antibodies (bNAbs) can be elicited, we identified, characterized, and tracked five neutralizing Ab lineages targeting the HIV-1-fusion peptide
Samantha Burton et al.
Journal of virology, 93(7) (2019-01-18)
The goals of preclinical HIV vaccine studies in nonhuman primates are to develop and test different approaches for their ability to generate protective immunity. Here, we compared the impact of 7 different vaccine modalities, all expressing the HIV-1 1086.C clade
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service